Cargando…

Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia

BACKGROUND: Septins are cytoskeletal proteins with filament forming capabilities, which have multiple roles during cell division, cellular polarization, morphogenesis, and membrane trafficking. Autoantibodies against septin-5 are associated with non-paraneoplastic cerebellar ataxia, and autoantibodi...

Descripción completa

Detalles Bibliográficos
Autores principales: Miske, Ramona, Scharf, Madeleine, Borowski, Kathrin, Rieckhoff, Nicole, Teegen, Bianca, Denno, Yvonne, Probst, Christian, Guthke, Kersten, Didrihsone, Ieva, Wildemann, Brigitte, Ruprecht, Klemens, Komorowski, Lars, Jarius, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061979/
https://www.ncbi.nlm.nih.gov/pubmed/36997937
http://dx.doi.org/10.1186/s12974-023-02718-9
_version_ 1785017402348535808
author Miske, Ramona
Scharf, Madeleine
Borowski, Kathrin
Rieckhoff, Nicole
Teegen, Bianca
Denno, Yvonne
Probst, Christian
Guthke, Kersten
Didrihsone, Ieva
Wildemann, Brigitte
Ruprecht, Klemens
Komorowski, Lars
Jarius, Sven
author_facet Miske, Ramona
Scharf, Madeleine
Borowski, Kathrin
Rieckhoff, Nicole
Teegen, Bianca
Denno, Yvonne
Probst, Christian
Guthke, Kersten
Didrihsone, Ieva
Wildemann, Brigitte
Ruprecht, Klemens
Komorowski, Lars
Jarius, Sven
author_sort Miske, Ramona
collection PubMed
description BACKGROUND: Septins are cytoskeletal proteins with filament forming capabilities, which have multiple roles during cell division, cellular polarization, morphogenesis, and membrane trafficking. Autoantibodies against septin-5 are associated with non-paraneoplastic cerebellar ataxia, and autoantibodies against septin-7 with encephalopathy with prominent neuropsychiatric features. Here, we report on newly identified autoantibodies against septin-3 in patients with paraneoplastic cerebellar ataxia. We also propose a strategy for anti-septin autoantibody determination. METHODS: Sera from three patients producing similar immunofluorescence staining patterns on cerebellar and hippocampal sections were subjected to immunoprecipitation followed by mass spectrometry. The identified candidate antigens, all of which were septins, were expressed recombinantly in HEK293 cells either individually, as complexes, or combinations missing individual septins, for use in recombinant cell-based indirect immunofluorescence assays (RC-IIFA). Specificity for septin-3 was further confirmed by tissue IIFA neutralization experiments. Finally, tumor tissue sections were analyzed immunohistochemically for septin-3 expression. RESULTS: Immunoprecipitation with rat cerebellum lysate revealed septin-3, -5, -6, -7, and -11 as candidate target antigens. Sera of all three patients reacted with recombinant cells co-expressing septin-3/5/6/7/11, while none of 149 healthy control sera was similarly reactive. In RC-IIFAs the patient sera recognized only cells expressing septin-3, individually and in complexes. Incubation of patient sera with five different septin combinations, each missing one of the five septins, confirmed the autoantibodies’ specificity for septin-3. The tissue IIFA reactivity of patient serum was abolished by pre-incubation with HEK293 cell lysates overexpressing the septin-3/5/6/7/11 complex or septin-3 alone, but not with HEK293 cell lysates overexpressing septin-5 as control. All three patients had cancers (2 × melanoma, 1 × small cell lung cancer), presented with progressive cerebellar syndromes, and responded poorly to immunotherapy. Expression of septin-3 was demonstrated in resected tumor tissue available from one patient. CONCLUSIONS: Septin-3 is a novel autoantibody target in patients with paraneoplastic cerebellar syndromes. Based on our findings, RC-IIFA with HEK293 cells expressing the septin-3/5/6/7/11 complex may serve as a screening tool to investigate anti-septin autoantibodies in serological samples with a characteristic staining pattern on neuronal tissue sections. Autoantibodies against individual septins can then be confirmed by RC-IIFA expressing single septins. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-023-02718-9.
format Online
Article
Text
id pubmed-10061979
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100619792023-03-31 Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia Miske, Ramona Scharf, Madeleine Borowski, Kathrin Rieckhoff, Nicole Teegen, Bianca Denno, Yvonne Probst, Christian Guthke, Kersten Didrihsone, Ieva Wildemann, Brigitte Ruprecht, Klemens Komorowski, Lars Jarius, Sven J Neuroinflammation Research BACKGROUND: Septins are cytoskeletal proteins with filament forming capabilities, which have multiple roles during cell division, cellular polarization, morphogenesis, and membrane trafficking. Autoantibodies against septin-5 are associated with non-paraneoplastic cerebellar ataxia, and autoantibodies against septin-7 with encephalopathy with prominent neuropsychiatric features. Here, we report on newly identified autoantibodies against septin-3 in patients with paraneoplastic cerebellar ataxia. We also propose a strategy for anti-septin autoantibody determination. METHODS: Sera from three patients producing similar immunofluorescence staining patterns on cerebellar and hippocampal sections were subjected to immunoprecipitation followed by mass spectrometry. The identified candidate antigens, all of which were septins, were expressed recombinantly in HEK293 cells either individually, as complexes, or combinations missing individual septins, for use in recombinant cell-based indirect immunofluorescence assays (RC-IIFA). Specificity for septin-3 was further confirmed by tissue IIFA neutralization experiments. Finally, tumor tissue sections were analyzed immunohistochemically for septin-3 expression. RESULTS: Immunoprecipitation with rat cerebellum lysate revealed septin-3, -5, -6, -7, and -11 as candidate target antigens. Sera of all three patients reacted with recombinant cells co-expressing septin-3/5/6/7/11, while none of 149 healthy control sera was similarly reactive. In RC-IIFAs the patient sera recognized only cells expressing septin-3, individually and in complexes. Incubation of patient sera with five different septin combinations, each missing one of the five septins, confirmed the autoantibodies’ specificity for septin-3. The tissue IIFA reactivity of patient serum was abolished by pre-incubation with HEK293 cell lysates overexpressing the septin-3/5/6/7/11 complex or septin-3 alone, but not with HEK293 cell lysates overexpressing septin-5 as control. All three patients had cancers (2 × melanoma, 1 × small cell lung cancer), presented with progressive cerebellar syndromes, and responded poorly to immunotherapy. Expression of septin-3 was demonstrated in resected tumor tissue available from one patient. CONCLUSIONS: Septin-3 is a novel autoantibody target in patients with paraneoplastic cerebellar syndromes. Based on our findings, RC-IIFA with HEK293 cells expressing the septin-3/5/6/7/11 complex may serve as a screening tool to investigate anti-septin autoantibodies in serological samples with a characteristic staining pattern on neuronal tissue sections. Autoantibodies against individual septins can then be confirmed by RC-IIFA expressing single septins. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-023-02718-9. BioMed Central 2023-03-30 /pmc/articles/PMC10061979/ /pubmed/36997937 http://dx.doi.org/10.1186/s12974-023-02718-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Miske, Ramona
Scharf, Madeleine
Borowski, Kathrin
Rieckhoff, Nicole
Teegen, Bianca
Denno, Yvonne
Probst, Christian
Guthke, Kersten
Didrihsone, Ieva
Wildemann, Brigitte
Ruprecht, Klemens
Komorowski, Lars
Jarius, Sven
Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia
title Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia
title_full Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia
title_fullStr Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia
title_full_unstemmed Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia
title_short Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia
title_sort septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061979/
https://www.ncbi.nlm.nih.gov/pubmed/36997937
http://dx.doi.org/10.1186/s12974-023-02718-9
work_keys_str_mv AT miskeramona septin3autoimmunityinpatientswithparaneoplasticcerebellarataxia
AT scharfmadeleine septin3autoimmunityinpatientswithparaneoplasticcerebellarataxia
AT borowskikathrin septin3autoimmunityinpatientswithparaneoplasticcerebellarataxia
AT rieckhoffnicole septin3autoimmunityinpatientswithparaneoplasticcerebellarataxia
AT teegenbianca septin3autoimmunityinpatientswithparaneoplasticcerebellarataxia
AT dennoyvonne septin3autoimmunityinpatientswithparaneoplasticcerebellarataxia
AT probstchristian septin3autoimmunityinpatientswithparaneoplasticcerebellarataxia
AT guthkekersten septin3autoimmunityinpatientswithparaneoplasticcerebellarataxia
AT didrihsoneieva septin3autoimmunityinpatientswithparaneoplasticcerebellarataxia
AT wildemannbrigitte septin3autoimmunityinpatientswithparaneoplasticcerebellarataxia
AT ruprechtklemens septin3autoimmunityinpatientswithparaneoplasticcerebellarataxia
AT komorowskilars septin3autoimmunityinpatientswithparaneoplasticcerebellarataxia
AT jariussven septin3autoimmunityinpatientswithparaneoplasticcerebellarataxia